ADVANCED SOLID TUMORS

This early-stage trial tests a new cell therapy called GK01 in 15 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells, which are trained in a lab to attack cancer cells. The main goals are to find …

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-stage trial tests an oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have specific KRAS gene mutations (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors. Particip…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-phase trial tests a new treatment called WTX-212C, which uses engineered red blood cells to target advanced solid tumors. About 24 adults who have run out of standard options will receive the drug intravenously. The main goal is to check safety and find the right dose,…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This early-stage study tests a new drug called GS-2426 in about 174 adults with advanced solid tumors that lack a gene called MTAP. The main goal is to see if the drug is safe and to find the best dose for future studies. Participants must have tried other treatments without succ…

This study tests a therapy that takes a patient's own immune cells, grows and strengthens them in a lab, and then gives them back to fight cancer. It is for people with advanced lung, liver, colorectal, or breast cancer that has spread. The goal is to see if this approach is safe…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-stage trial tests a personalized cell therapy called GK01 for people with advanced solid tumors who have no standard treatment options left. The therapy uses a patient's own immune cells, trained to attack their tumor. The main goal is to check safety, with a secondary…

This study tests an experimental drug, SKB118, in about 332 adults aged 18–75 with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The trial has three stages: finding the right dose,…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This study tests a new drug called SKB565 in 180 adults (ages 18-75) with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The goal is to see if the drug is safe and can shrink tumors. The study has three parts: finding the right …

This early-stage study tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—in about 60 people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and see if the combina…

This early-stage study tests a new drug, BPI-572270, in adults with advanced solid tumors (lung, colorectal, pancreatic) that have specific RAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 participants who …

This study tests an experimental daily pill, FS-207, in people with advanced solid tumors that have a specific DNA feature called MSI-H. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink or control the cancer. About 156 adults whose canc…

This early-stage study tests a new drug called HF50 in about 45 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also watch for any signs that the drug shrinks tu…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-stage study tests a new drug called CS5007 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to find a safe dose and see if the drug ca…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This early-phase study tests two experimental drugs, IMM2510 and IMM01, given together to people with advanced solid tumors that have not responded to at least one prior treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth. …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study offers continued treatment with the experimental drug RVU120 to adults with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from it in an earlier study. Participants must have received at least 5 cycles of…

This early-phase study tests a new drug called WSK-IM02 in 9 adults with advanced solid tumors that have spread and caused fluid buildup in the chest or belly. The drug is given directly into the fluid space to see if it is safe and can shrink tumors or control the fluid. Partici…